Effects of administration of oxytocin on embryonic survival in progestogen supplemented cattle.
Embryonic survival after administration of oxytocin (OT) was examined in 42 beef cows. All cows were bred (Day 0) and randomly assigned to receive either 25 mL saline (CON; n = 10), 100 IU OT + 20 mL saline (OT; n = 12), 100 IU OT + 1 g flunixin meglumine (OT + FM; inhibitor of prostaglandin endoperoxide synthase; n = 10), or 100 IU OT + lutectomy (OT + LUT; n = 10) administered (i.m.) at 8-h intervals on Days 5-8 after mating. Lutectomies were performed by transrectal digital pressure prior to initiation of treatments (0600, Day 5). All cows were fed 4 mg/head/day of melengesterol acetate (an orally administered exogenous progestogen) through Days 3-30 and were bled by jugular venipuncture at 0600 and 0700 h on Day 5 for determination of 13,14-dihydro-15-keto-PGF2a (PGFM). Pregnancy rates, as determined by transrectal ultrasonography at Day 30, were reduced in OT (33.3%) and OT + LUT (30%) groups compared to CON and OT + FM (80%; p < or = 0.03). Number of short cycles were increased in OT (n = 6/12) group compared to CON (n = 0/10; p < or = 0.009) and OT + FM (n = 1/10; p < or = 0.045). Mean change in PGFM from the 0600 to 0700 h bleed was different (p < or = 0.01) between the OT + LUT (31.6 +/- 11.0 pg/mL) group versus CON (-11.2 +/- 10.6 pg/mL) and OT + FM (-13.8 +/- 10.6 pg/mL) groups. Administration of oxytocin appears to decrease embryonic survival by stimulating uterine PGF2a. Thus, previous reports indicating that removal of the corpus luteum during progestogen supplementation and prior to PGF2a administration increases embryonic survival can be explained through interruption of the luteal oxytocin-uterine PGF2a feedback loop.
Lemaster
J W
JW
Department of Animal Science, University of Tennessee, Knoxville, USA.
Seals
R C
RC
Hopkins
F M
FM
Schrick
F N
FN
D000818:Animals; D002417:Cattle; D015237:Dinoprost / Q000031:analogs & derivatives / Q000032:analysis / Q000378:metabolism; D005314:Embryonic and Fetal Development / Q000187:drug effects*; D004971:Estrus / Q000187:drug effects / Q000378:metabolism; D005260:Female; D010121:Oxytocin / Q000494:pharmacology*; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000032:analysis; D018873:Pregnancy Rate; D011270:Pregnancy, Animal / Q000187:drug effects*; D011374:Progesterone / Q000494:pharmacology*; D011863:Radioimmunoassay; D014599:Uterus / Q000187:drug effects
D011257:Pregnancy Proteins; C048000:pregnancy protection protein P4; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D011374:Progesterone; D010121:Oxytocin; D015237:Dinoprost